Abstract:In an ongoing investigation of 20-sulfonylamidine derivatives (9, YQL-9a) of camptothecin (1) as potential anticancer agents directly and selectively inhibiting topoisomerase (Topo) I, the sulfonylamidine pharmacophore was held constant, and a camptothecin derivatives with various substitution patterns were synthesized. The new compounds were evaluated for antiproliferative activity against three human tumor cell lines, A-549, KB, and multidrug resistant (MDR) KB subline (KBvin). Several analogs showed comparable or superior antiproliferative activity compared to the clinically prescribed 1 and irinotecan (3). Significantly, the 20-sulfonylamidine derivatives exhibited comparable cytotoxicity against KBvin, while 1 and 3 were less active against this cell line. Among them, compound 15c displayed much better cytotoxic activity than the controls 1, 3, and 9. Novel key structural features related to the antiproliferative activities were identified by structure-activity relationship (SAR) analysis. In a molecular docking model, compounds 9 and 15c interacted with Topo I-DNA through a different binding mode from 1 and 3. The sulfonylamidine side chains of 9 and 15c could likely form direct hydrogen bonds with Topo I, while hydrophobic interaction with Topo I and π-π stacking with double strand DNA were also confirmed as binding driving forces. The results from docking models were consistent with the SAR conclusions. The introduction of bulky substituents at the 20-position contributed to the altered binding mode of the compound by allowing them to form new interactions with Topo I residues. The information obtained in this study will be helpful for the design of new derivatives of 1 with most promising anticancer activity.

Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors

Design, Synthesis and Antitumor Activity of Non-Camptothecin Topoisomerase I Inhibitors

Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives As Potential Topoisomerase I Inhibitors by Scaffold Modification.

Synthesis Of Novel Benzoxanthone Analogues As Non-Camptothecin Topoisomerase I Inhibitors

Design, Synthesis and Antitumor Activity of 3-Substituted Quinolone Derivatives (I)

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Design, synthesis and biological evaluation of novel mansonone E derivatives prepared via CuAAC click chemistry as topoisomerase II inhibitors.

Novel 4-(4-substituted Amidobenzyl)furan-2(5H)-one Derivatives As Topoisomerase I Inhibitors.

Design, Synthesis, Cytotoxic Activity and Molecular Docking Studies of New 20(S)-Sulfonylamidine Camptothecin Derivatives

Synthesis and Antitumor Activity of Novel 10-Substituted Camptothecin Analogues.

Design, Synthesis and Biological Evaluation of Novel Homocamptothecin Analogues As Potent Antitumor Agents.

Development of Indenoisoquinoline Derivatives as Novel Topoisomerase 1 Inhibitors

Synthesis and Biological Evaluation of 6-Substituted Indolizinoquinolinediones As Catalytic DNA Topoisomerase I Inhibitors.

Synthesis and Antitumor Activity of the Hexacyclic Camptothecin Derivatives.

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors

Synthesis and Biological Evaluation of Xanthone Derivatives As Anti-Cancer Agents Targeting Topoisomerase II and DNA

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

Synthesis, cytotoxic activities and structure-activity relationships of topoisomerase I inhibitors: indolizinoquinoline-5,12-dione derivatives.

Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.

Recent Advances in Non-camptothecin DNA Topoisomerase I Inhibitors as Anticancer Drugs